StockData
Guided Therapeutics Inc logo

Guided Therapeutics Inc (GTHP) stock

GTHPOTCElectromedical & Electrotherapeutic ApparatusFiscal year ends December 31
Financials through Q2 FY2026, quarter ended Jun 30, 2026Last filing: 10-Q on Nov 16, 2026Score 4/30
$0.16−0.03 (-15.79%)

Close on Oct 19, 2026Market cap $15.45MP/E –Yield –

Guided Therapeutics r&d expenses

Research and development expenses are spending on new products and technology.

Guided Therapeutics's R&D Expenses for the twelve months ending Jun 30, 2026 was $342.00K, down 25.3% year over year. For fiscal 2025 it was $469.00K, down 10.8% from the year before. Over ten years it grew -10.8% a year on average. The highest annual figure on record is $3.23M in fiscal 2012.

Annual r&d expenses

PeriodPeriod endValueChange
FY2025Dec 31, 2025$469.00K-10.8%
FY2024Dec 31, 2024$526.00K+130.7%
FY2023Dec 31, 2023$228.00K+196.1%
FY2022Dec 31, 2022$77.00K+11.6%
FY2021Dec 31, 2021$69.00K-51.7%
FY2020Dec 31, 2020$143.00K+17.2%
FY2019Dec 31, 2019$122.00K-50.0%
FY2018Dec 31, 2018$244.00K-26.9%
FY2017Dec 31, 2017$334.00K-54.4%
FY2016Dec 31, 2016$733.00K-50.4%
FY2015Dec 31, 2015$1.48M-47.0%
FY2014Dec 31, 2014$2.79M+1.7%
FY2013Dec 31, 2013$2.74M-15.0%
FY2012Dec 31, 2012$3.23M+16.1%
FY2011Dec 31, 2011$2.78M+54.0%
FY2010Dec 31, 2010$1.81M–

Quarterly r&d expenses

Change is against the same quarter a year earlier.

PeriodPeriod endValueChange
Q2 FY2026Jun 30, 2026$34.00K-74.4%
Q1 FY2026Mar 31, 2026$45.00K-39.2%
Q4 FY2025Dec 31, 2025$127.00K-9.3%
Q3 FY2025Sep 30, 2025$136.00K+22.5%
Q2 FY2025Jun 30, 2025$133.00K-40.1%
Q1 FY2025Mar 31, 2025$74.00K+37.0%
Q4 FY2024Dec 31, 2024$140.00K+62.8%
Q3 FY2024Sep 30, 2024$111.00K+60.9%
Q2 FY2024Jun 30, 2024$222.00K+236.4%
Q1 FY2024Mar 31, 2024$54.00K+671.4%
Q4 FY2023Dec 31, 2023$86.00K+120.5%
Q3 FY2023Sep 30, 2023$69.00K+762.5%
Q2 FY2023Jun 30, 2023$66.00K+633.3%
Q1 FY2023Mar 31, 2023$7.00K-66.7%
Q4 FY2022Dec 31, 2022$39.00K+129.4%
Q3 FY2022Sep 30, 2022$8.00K-50.0%
Q2 FY2022Jun 30, 2022$9.00K-55.0%
Q1 FY2022Mar 31, 2022$21.00K+31.3%
Q4 FY2021Dec 31, 2021$17.00K-22.7%
Q3 FY2021Sep 30, 2021$16.00K-61.0%
Q2 FY2021Jun 30, 2021$20.00K-63.6%
Q1 FY2021Mar 31, 2021$16.00K-33.3%
Q4 FY2020Dec 31, 2020$22.00K+144.4%
Q3 FY2020Sep 30, 2020$41.00K+78.3%
Q2 FY2020Jun 30, 2020$55.00K+27.9%
Q1 FY2020Mar 31, 2020$24.00K-48.9%
Q4 FY2019Dec 31, 2019$9.00K-87.0%
Q3 FY2019Sep 30, 2019$23.00K-46.5%
Q2 FY2019Jun 30, 2019$43.00K-30.6%
Q1 FY2019Mar 31, 2019$47.00K-31.9%
Q4 FY2018Dec 31, 2018$69.00K-16.9%
Q3 FY2018Sep 30, 2018$43.00K-37.7%
Q2 FY2018Jun 30, 2018$62.00K-30.3%
Q1 FY2018Mar 31, 2018$69.00K-24.2%
Q4 FY2017Dec 31, 2017$83.00K-60.1%
Q3 FY2017Sep 30, 2017$69.00K-20.7%
Q2 FY2017Jun 30, 2017$89.00K–
Q1 FY2017Mar 31, 2017$91.00K–
Q4 FY2016Dec 31, 2016$208.00K–
Q3 FY2016Sep 30, 2016$87.00K–

More Guided Therapeutics figures

See a number that looks wrong?